Gene Therapy in Vivo for Hepatocellular Carcinoma Using Double Suicide Genes Combined with IL-12 Gene

黄嘉凌,刘燕艳,方壮伟,申权,刘然义,吕明德

DOI: https://doi.org/10.3781/j.issn.1000-7431.2004.05.014

2004-01-01

Tumori

Abstract:Objective To investigate the effectiveness of gene therapy in vivo for hepatocellular carcinoma using double suicide genes combined with IL-12 gene. Methods SCID mice were subcutaneoulsy injected with HepG2 cells, 5×105 (in 0. 2 ml) in each flank, and intraperitoneally (ip) injected with 2×107(in 0. 5 ml) human PBL. When tumor reached a diameter of 0. 6 cm, the mice were separated into four groups and intratumoral injected with 5×105 (in 0. 1 ml) MMC-treated HepG2-IL-12 cells, 5× 105(in0.1 ml) HepG2-pALBeAFP-CD/TK cells or 5×105 (in 0. 05 ml) HepG2-pALBeAFP-CD/TK cells + 5×105 (in 0. 05 ml) MMC-treated HepG2-IL-12 cells in the left flank, and ip injected with PBS or GCV 100mg/kg+ 5-FC 500 mg/kg for 10 days: group Ⅰ, HepG2-IL-12 + GCV, 5-FC; and group Ⅱ . HepG2-pALBeAFP-CD/TK + PBS; group Ⅲ , HepG2-pALBeAFP-CD/ TK+GCV,5-FC; and groupⅣ , HepG2-pALBeAFP-CD/TK + HepG2-IL-12 + GCV, 5-FC. Tumor size determination and routine pathological study were performed on day 5 after treatment. Results On the left flank, there was a decrease of tumor volume of 20. 5% , 54. 9% , and 87. 6% on day 30 in group Ⅰ, Ⅲ and Ⅳ, compared with group Ⅱ, respectively. And there was distinct difference among group Ⅰ , Ⅲ and Ⅳ. On the right flank, tumor exhibited palpable volume reduction of 23. 3% , 24. 9% and 45. 0% , respectively in group Ⅰ , Ⅲand Ⅳ , compared to group Ⅱ . Conclusion The pALBeAFP-CD/TK-GCV. 5-FC system can efficiently treat HCC in vivo. In immune competent mouse, local expression of IL-12 can enhance the therapy effect and distal bystander effect of double suicide gene therapy.